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The cellular phosphoprotein, p53, is expressed at high levels in cells trans-
formed by a variety of agents including DNAandRNA viruses, and carcinogens
(reviewed in 1 and 2) . p53 expression is not restricted to tumor cell lines; fresh
human tumor cells from patients with colorectal and mammary tumors exhibit
elevated expression of p53 (3). Overproduction of p53 protein in certain cells
has been shown (4-6) to confer an enhanced tumorigenic phenotype. The recent
demonstration of the capacity of p53 to immortalize primary cells (7) and to
cooperate with the activated c-Ha-ras-1 oncogene in the transformation of rat
embryo fibroblasts (7-9) indicates that the p53 gene has oncogenic potential,
and consequently can be classified as an oncogene . p53 cannot be considered a
marker for malignancy, however, since p53 protein synthesis is observed (10-
13) after mitogen or serum stimulation of certain quiescent normal cells . More-
over, in the study cited above (3), 4 out of 19 fibroadenomas (benign breast
tumors) examined had increased levels ofp53 .
It is possible that certain oncogene products that confer an establish-
ment/immortalizing phenotype (such as myc, p53, Ela) on primary cultures
causing them to grow indefinitely may also play a role during normal and
malignant stem cell self-renewal . Self-renewal is the defining property of stem
cells, which allows these cells to generate essentially identical progeny in the
absence of further differentiation . In this study, we focus on this possibility by
examining p53 expression in leukemic blast cells from patients with acute
myeloblastic leukemia (AML) .' AML is a clonal hemopathy that is believed to
arise in pluripotent stem cells following multiple carcinogenic events (14-16). It
has been proposed that these events give rise to malignant stem cells with the
capacity to produce the relatively normal myelopoietic cells and blast cells that
characterize this disease .
Leukemic blast populations may be considered a lineage, maintained by asmall
number of progenitors (17) ; these are assayed by their capacity to form blast
colonies in methylcellulose (18-20), andmay be regarded as malignant stem cells
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' Abbreviations used in this paper:
￿
AML, acute myeloblastic leukemia ; CM, conditioned medium ;
LCM, leukocyte-conditioned medium ; NET buffer, buffer containing NaCl, EDTA, and Tris, as
defined in Materials and Methods ; PE2, secondary plating efficiency .
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since they possess self-renewal capacity. The capacity of blasts for renewal is
usually assayed by replating either single colonies or cells pooled from primary
colonies (19). The former method shows marked colony-to-colony variation ; in
the latter, the plating efficiency of cells from pooled primary colonies (secondary
plating efficiency [PE2]) can be considered as the average self-renewal capacity
of the leukemic blast stem cells in each patient. A significant correlation has been
found between low PE2 values and success in obtaining remission with intensive
chemotherapy (21, 22).
Materials and Methods
(:ells.
￿
Blasts were obtained from the peripheral blood of patients with AML. These
patients were compared to a larger historical control consisting of patients seen at our
institution in the last three years, and were found to be representative in terms of age,
sex, FAB classification, and clinical status. Furthermore, the blast colony assay results
obtained using cells from these patients were not significantly different from the historical
control population (p = 0.28, n = 82 ; Mann-Whitney U test). After isolation, only
mononuclear cell populations that were >95% blasts by standard morphological staining
were used in this study. Normal marrow cells were obtained from healthy marrow
transplantation donors and from recipients, 28 d after transplant. Mononuclear cell
fractions were prepared as described previously (20) by separation through Ficoll-Hypaque
or Percoll (p = 1 .077 g/ml) . The suspension was then depleted of T lymphocytes using a
second Ficoll-Hypaque separation after erythrocyte rosette formation. Some normal bone
marrow specimens were also depleted ofadherent cells. The T lymphocyte-depleted cells
were either cultured immediately or preserved by freezing in liquid nitrogen in 10%
DMSO, 40% a-MEM, and 50% FCS.
OCI-Ly2 is a human lymphoma cell line obtained from Drs. M. Tweeddale and H.
Messner (Ontario Cancer Institute).
Blast Colony Assay. Blast colony formation in culture was obtained as described
previously (20). The T lymphocyte-depleted mononuclear cells were mixed with 0.8%
methylcellulose in a-MEM supplemented with 20% FCS and 10% PHA-leukocyte condi-
tioned medium (PHA-LCM) and cultured in 35-mm Lux culture dishes at 37°C. After 7
d, the colonies were counted and the dishes were pooled. Cells were washed twice in a-
MEM and replated in 0.8% methylcellulose, 20% FCS, and 10% PHA-LCM at a concen-
tration of 104 cells per 0.1 ml in a 6-mm microwell of a flat-bottom Linbro tissue culture
tray. Secondary colonies were counted after 7 d of incubation, and the values are expressed
as the secondary plating efficiency (colonies per 104 cells, or PE2).
In Vivo Metabolic Labelling of p53.
￿
Because many of the samples had been stored
frozen, the cells were thawed and incubated overnight at 37°C in a-MEM containing 10%
FCS, with or without PHA-LCM, to allow recovery of metabolic activity . In addition,
certain samples, including fresh T lymphocyte-depleted normal mononuclear marrow
cells, were incubated for 5 d in medium conditioned by cells of the continuous bladder
carcinoma line HTB9 (HTB9-CM) (23) to optimize hematopoietic cell growth before
metabolic labelling. PHA-LCM and HTB9-CM were essentially identical in their ability
to stimulate the growth in culture of granulocyte/macrophage colonies and erythroid
colonies from normal bone marrow, as well as leukemic blast colonies from AML blood
(23) . ^-10' cells were labelled for I h at 37°C with 0.2 mCi of ["S]methionine in 0.5 ml
a-MEM lacking methionine, or for 3 h at 37°C with 1 .0 mCi ["P]orthophosphate in 2.0
ml a-MEM lacking phosphate. Cells were then washed with PBS and lysed for 30 min on
ice with 0.3 ml lysis buffer (1% NP-40, 150 mM NaCI, 50 mM Tris, pH 8, 0.5 mM
PMSF). Lysates were cleared by centrifugation for 1 min, and by the addition of 0.5 ml
of a 10% suspension of formalin-treated Staphylococcus aureus Cowan 1 cells (Pansorbin;
Calbiochem-Behring, San Diego, CA) for 15 min on ice, followed by centrifugation and
retention of the supernatant. For [s5S]methionine-labelled cells, lysate volumes corre-
sponding to equal numbers ofTCA-insoluble radioactivity (10' cpm) were immunoprecip-SMITH ET AL .
￿
753
itated overnight at 10°C with antibody in 400 Al NET gel buffer (150 mM NaCl, 5 mM
EDTA, 50 mM Tris,pH 7.4, 0.05% NP-40,0.02% sodium azide, 0.25% gelatin) . Immune
complexes were collected on 50 A,1 S. aureus cells as above, washed twice in NET gel
buffer, and then eluted into 30 p1 sample buffer (2% SDS, 10% glycerol, 0.1% bromo-
phenol blue, 25 mM Tris, pH 6.8) by heating at 70°C for 10 min. S. aureus cells were
removed by centrifugation, and samples were loaded onto a 12.5% polyacrylamide gel in
the presence of SDS. Electrophoresis was at 35 mA until the blue dye front reached the
bottom ofthe gel. Gels were fixed in 7.5% acetic acid/25% methanol for 30 min before
being dried and exposed to Kodak XAR-5 film.
Genomic DNA Analysis.
￿
DNA was extracted from blast cellsby the method ofBlin and
Stafford (24) using proteinase K and SDS. Samples (10 jag) were digested to completion
withthe appropriaterestriction enzyme, andseparated byelectrophoresis on 0.8% agarose
gels.The DNAinthegels wastransferredto nitrocellulose filtersas describedby Southern
(25). The filter was hybridized using standard conditions (26), with a [82p]-labelled DNA
fragment obtained from the human p53 cDNA clone p102 (27) after digestion with Nco
I and Bam HI. These enzymes liberate a p53 cDNA insert of 1,410 bp.
Results
Synthesis ofp53 protein was measured in leukemic blast cells from 34 patients
with AML. Cells were labelled metabolically with [35S]methionine, and in certain
instances with [32P]orthophosphate . Because many ofthesamples hadbeenstored
frozen, the cells were thawed and incubated overnight at 37°C in a-MEM
containing 10% FCS to allow recovery of metabolic activity before labelling. In
addition, certain samples were incubated for 5 d in HTB9-CM (23) to optimize
blast cell growth before metabolic labelling. Radiolabelled p53 was immunopre-
cipitated from cellular extracts, subjected to electrophoresis in SDS-polyacryl-
amide gels, and visualized after autoradiography (Fig. 1).
p53 was present in the blast cells of 19 out of 34 AML patients. p53 protein
was not detected in lymphocyte- and adherent cell-depleted mononuclear cells
from normal bone marrow, or from regenerating marrow from patients with
transplants when freshly obtained or after culture under conditions identical to
those used to detect p53 in blast cells. We also did not detect p53 protein in
proliferating early-passage cultures of human fibroblasts (data not shown) . The
absence of detectable p53 protein in normal human cells is consistent with
numerous previous reports (1, 3, 28-30).
The 15 blast cell preparations in which p53 protein was not detected included
blast cells from two patients, which were cultured for 5 d in conditioned medium
and shown to be proliferating on the basis of increasing cell number, increasing
colony number in the blast colony assay (20) after plating on methylcellulose,
and by their DNA-staining (Hoescht) profile on a FACS. Hence, proliferation in
the presence of HTB9-CM, which is necessary for the maintenance ofAML blast
populations in culture, is not sufficient to produce detectable p53 protein
synthesis in certain leukemic blast cells.
It is apparent in Fig. 1 that heterogeneity of human p53 protein exists. Patient
1, for example, has a single species ofp53, whereas patient 2 has two or possibly
three distinct forms ofp53. A novel form of heterogeneity was uncovered when
samples were screened with two antibodies against p53: an mAb, PAb421 (31),
and polyclonal antibody from human serum, P407 (32). p53 protein in the blast
cells of patient 3 (Fig. 1) was recognized by the polyclonal serum but not by the
PAb421 mAb. We confirmed this observation by labelling the blast cells of this754
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FIGURE 1 .
￿
Expression of p53 protein in human cells . Blast cells from three patients with
AML were obtained as described in Materials and Methods. Blast cells from patient 1 were
incubated overnight in a-MEM containing 10% FCSbefore labelling . Blast cells from patients
2and 3 were grown in HTB9-CM (23) for 5 dbefore labelling . OCI-Ly2 is ahuman lymphoma
cell line . Normal bone marrow (NBM) consists of Percoll-separated mononuclear cells from
marrow obtained from a donor of marrow for transplantation . ^-10' cells were labelled for 1
h at 37°C with 0.2 MCi of [s5S]methionine in 0.5 ml a-MEM lacking methionine. Labelled
extracts were immunoprecipitated with the following antibodies : lane a, PAb419 (31) (control
mAb that recognizes a 35 kD cellular protein) ; b, PAb421 mAb against p53 (31) ; c, human 7
globulin ; d, P407 anti-p53 serum (32) .
patient with [32P]orthophosphate and immunoprecipitating the p53 protein, as
shown in the autoradiogram in Fig . 2 . OCI-Ly2 is a human lymphoma cell line
that contains phosphorylated p53 that is recognized by both antibodies, and it is
included as a positive control. The p53 protein present in the blast cells of patient
3, however, is only recognized by the P407 serum . Heterogeneity of p53 has
been described previously ; that observed as differences in mobility is seen in the
samples from patients 2 and 3 (Fig . 1) (28, 30) . Antigenic heterogeneity has also
been observed (11, 33) .
P407 serum is polyclonal, and likely contains antibodies toavariety ofantigens,
in addition to p53 . However, both the size and phosphorylated status of the
protein recognized by the P407 serum, in the case of patient 3, indicate that the
protein is an immunologically altered form ofp53 in which the epitope formAb
PAb421 is either missing or masked . Whereas two distinct species of p53 are
present in the blast cells of patient 3 after [35S]methionine labelling (Fig. 1), only
one species appears to be phosphorylated (Fig . 2) . We have no satisfactory
explanation for this observation . It is unlikely that the separation achieved it) the
polyacrylamide gel displayed in Fig . 2 was inadequate to resolve the two species
of p53, although this possibility cannot be dismissed . More detailed analysis ofSMITH ET AL .
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FIGURE 2 .
￿
Detection ofphosphorylated p53 protein inhuman cells . OCI-Ly2 cells andAML
blast cells from patient 3 (see legend to Fig . 1) were labelled for 3 h with 1 MCi [32P)-
orthophosphate in 2 ml a-MEM lacking phosphate . Lysate were prepared and proteins
immunoprecipitated as described in Materials and Methods . Equal volumes of lysates were
subjected to immunoprecipitation . Lane a, PAb419 control mAb; b, PAb421 tnAb against
p53 ; c, human ti globulin ; d, P407 anti-p53 serum .
the biochemical properties of p53 protein (for example, by identifying and
comparing phosphorylated amino acids in ["P]-labelled p53 proteins from blast
cells and OCY-Ly2) may provide insight into the nature and significance of the
observed heterogeneity.
To determine whether the absence of p53 expression was the result of
rearrangement or loss of the cellular p53 gene, as shown previously in other
cellular systems (5, 34, 35), genomic DNA from blast cells was digested with Pvu
11, Pst 1, Bam Hl, or Hind III, and analyzed by the Southern blot technique
(25) . The probe used for these experiments was a Nco I/Bam HI insert from a
cDNA clone, p102, containing human p53-specific sequences (27) . A represent-
ative autoradiogram is shown in Fig . 3 . No differences in the p53 gene were
detected at this level of resolution in p53-producing and -nonproducing blast
cells. Any alteration occurring at the extreme 5' end of the p53 gene may have
been missed in this analysis, however, since the cDNA clone used as a probe is
not full length, and is missing sequences at the 5' end.
The secondary plating efficiency (PE2) of AML blast populations provides a756
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FIGURE 3 .
￿
Southern blot of genomic DNA from AML blast cells . DNA (10,ug) was digested
with restriction endonucleases Pvu II, Pst I, Bam HI, or Hind III, and separated on a 0.8%
agarose gel . The DNA in the gel was transferred to a nitrocellulose filter as described by
Southern (25) . The filter was hybridized to the Nco I/Bam HI fragment of the human p53
cDNA clonep102 located between nucleotides 177and 1,587 (27) . (A) GenomicDNAisolated
from blast cells of a patient not expressing p53 protein . (B) GenomicDNA isolated from cells
that do express p53 protein .
measure of the renewal capacity of blast progenitors (19) . To examine the
possible involvement of p53 in the process of self renewal, the PE2 values of the
19 blast populations positive for p53 expression were determined and compared
with the PE2 values of the 15 blast populations where p53 protein was not
detected . The extent to which PE2 correlates with p53 synthesis is shown in Fig .
4 . A highly significant correlation between p53 expression and a high PE2 value
was obtained by the Mann-Whitney U test (p = 0.0001) .
Discussion
Metabolic labelling of cells, followed by lysis and immunoprecipitation was
used as an assay to assess p53 protein synthesis in the blast cells of patients with
AML. There are a number of limitations in this type of assay, which have been
discussed previously in detail (29) . In particular, this assay cannot be used to
determine the steady-state level of p53, since the half-life of this protein is
variable in different cell types . At best, this assay provides a measure for the rate
of p53 protein synthesis . The major difficulty with the assay centers on the1000
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FIGURE 4.
￿
PE2 (secondary plating efficiency) of blast cells from 34 AML patients. PE2 was
measured in the blast colony assay as described (20). The presence of detectable p53 protein
was determined by metabolic labelling as described in Materials and Methods. p53` and p53-
cells are significantly different with respect to PE2 (p = 0.0001 ; Mann-Whitney U test).
interpretation of negative data . The absence of immunoprecipitable p53 may be
the result of any one of the following: inefficient uptake of [35S]methionine,
inefficient incorporation of [35S]methionine into protein, large intracellular pools
of competing methionine, absence or occlusion of the epitope on p53 to which
the antibody is directed .
To eliminate some of these objections, we routinely immunoprecipitate ali-
quotsof lysate containing equal numbers of TCA-insoluble counts. Furthermore,
we routinely perform a control immunoprecipitation with mAb PAb419 (31)
that recognizes a ubiquitous 35 kD protein (p35) (36). The presence of p35 on
autoradiograms ensures that labelling artifacts have not occurred. In Fig. 1, p35
is present in each of the lanes where this antibody was used . We show that normal
bone marrow cells do incorporate [35S]methionine into p35 under the same
conditions that fail to radiolabel p53. We recognize the possibility that normal
bone marrow cells, and certain blast cells where p53 cannot be detected, may
express p53 at levels too low to be detected by this assay. If p53 protein turnover
was accelerated in these cells, we would likely not detect it using the metabolic
labelling protocol described here .
To compare the sensitivity of metabolic labelling with other assays for p53,
cellular extracts from p53+ leukemic blast cells were prepared and examined for
p53 by Western blotting (37) and by a solid-phase RIA for p53 (29). In neither
case was a p53 signal detected (data not shown), indicating that the steady-state
level of p53 protein remains low even in leukemic blast cells that are clearly
expressing the protein. Hence, for an unstable protein like p53, measurement
of synthesis by metabolic labelling is more sensitive than measurement of steady
state level.
The metabolic labelling studies allow us to draw several conclusions: (a) p53 is
expressed in fresh leukemic blast cells, (b) normal myeloid cells present in bone
i
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marrow do not synthesize detectable p53, (c) human p53 protein exhibits struc-
tural heterogeneity on SDS-polyacrylamide gels, (d) heterogeneity ofp53 expres-
sion exists in blast cells from AML patients, and (e) this heterogeneity in p53
expression shows a striking correlation with the secondary plating efficiency of
blast cells in the blast colony assay.
If, as we have suggested (17), the blasts ofAML are an abnormal lineage, it is
difficult to find an appropriate normal control population for comparison . If
blasts have normal counterparts, as would be implied by models postulating
blocked differentiation (see, for example, 38), these counterparts would be
present as very rare primitive cells in normal marrow. From either viewpoint,
normal marrow mononuclear cells, depleted of T lymphocytes, may be the most
suitable control population. These cells were cultured, moreover, in conditioned
medium that supports cell proliferation and is known to contain hematopoietic
growth factors including granulocyte/macrophage colony stimulating factor
(GM-CSF), and erythroid-potentiating activity (EPA) (23). For all the above
reasons, we consider our inability to detect p53 in normal marrow cells and in
certain leukemic blast cell populations using mAb (PAb421) and polyclonal
antibody (P407) to be significant and not artifactual. The presence of p53 in
some leukemic blast populations and the absence of detectable p53 in normal
myelopoietic cells is consistent with the model that AML blast cell populations
form an independent lineage characterized by abnormal differentiation and
possibly by abnormal gene expression (17).
The mechanism for regulating p53 expression in leukemic blast cells and for
generating the heterogeneity in expression ofp53 that is observed is not under-
stood. In our initial attempts to characterize this heterogeneity, we examined
the structure of the p53 gene in blast cells and found no differences between
p53-producing and -nonproducingcells. In experiments using mouse and human
cell lines, evidence has been obtained that the levels of p53 protein are not
correlated with the amount of p53 mRNA, indicating that the amount of p53
protein in these cells is regulated at the posttranscriptional level, perhaps through
changes in protein stability (27, 39-41) . Experiments are presently in progress
to examine p53 mRNA levels in blast cells to determine whether the findings
are similar to those obtained using cell lines.
An immunologically distinct form of p53, not displaying the epitope for mAb
PAb421 (31) was identified in the blast cells ofone patient. Previously, Milner
(11) showed that the p53 protein molecules in quiescent mouse lymphocytes do
not display the epitope for PAb421, whereas the p53 protein in proliferating
lymphocytes do. Wolfet al. (33) have also identified an immunologically distinct
form of p53 that does not express the PAb421 epitope. This epitope has been
mapped to the carboxyl-terminus on p53 (42). The significance of this alteration
on p53 is not clear.
The highly significant correlation that is observed between p53 expression
and the secondary plating efficiency (PE2) of leukemic blast cells suggests that
p53 may play a role in events occurring in the process ofselfrenewal. Expression
of p53 has been shown to extend the life span of primary cells in culture, and
also to transform these cells in collaboration with activated Ha-ras (7-9). Taken
together, these data support the suggestion of Buick and Pollak (43) that cellularSMITH ET AL .
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immortalization may represent a deregulation of the self renewal process in stem
cells through inappropriate expression of certain cellular oncogenes .
Exposure of blast cells in culture to a number of agents has been shown to
change their PE2 value (44). 12-o-tetradecanoyl phorbol-13-acetate (TPA) and
5-azacytidine increase PE2, whereas interferon and cytosine arabinoside decrease
PE2. If p53 is involved in the process of self renewal, then we would expect these
agents to affect p53 expression in the same way as they affect PE2. Experiments
along these lines are presently in progress. More definitive proof must await the
direct genetic manipulation of p53 expression in leukemic blast cells and dem-
onstration that the PE2 value of these cells can be regulated.
Summary
We have investigated whether the p53 oncogene is expressed in the blast cells
of patients with acute myeloblastic leukemia. p53 protein was detected in the
blast cells of 19 out of 34 patients, but not in normal myelopoietic cells. We find
a highly significant correlation between p53 protein synthesis in leukemic blast
cells and the secondary plating efficiency of these cells (P = 0 .0001) . The latter
provides an estimate for the self renewal capacity of progenitor cells in the blast
population. These data indicate that p53 may be involved in leukemic stem cell
renewal.
We thank Dr. M. Minden for the blast cell genomic DNA, Drs. H. Messner and M.
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